GlassScriptPhysician profile
James M Zehner
NPI 1851405567
$2,024.02
in general payments reported to CMS, 2019-2025
25 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $62.68 · 2021: $217 · 2022: $263 · 2023: $299 · 2024: $523 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $427.72 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $256.49 | 2021-2025 | Airsupra, Breztri |
| Pfizer INC. | $150.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $107.50 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $107.17 | 2024-2025 | Repatha, Otezla, Repatha |
| Daiichi Sankyo INC. | $76.12 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $47.02 | 2020-2025 | Rotateq, Vaxelis, Gardasil 9 |
| Organogenesis INC. | $44.14 | 2022-2023 | Puraply |
| Sumitomo Pharma America, INC. | $41.66 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $37.15 | 2020-2023 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $36.21 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $34.83 | 2024 | Yupelri |
| Medtronic, INC. | $34.39 | 2025 | Inceptiv |
| Lilly USA, LLC | $31.03 | 2020-2023 | Mounjaro, Trulicity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $26.39 | 2025 | Floseal |
| Neurocrine Biosciences, INC. | $24.87 | 2025 | |
| Insmed, INC. | $18.60 | 2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.33 | 2024 | Ofev |
| Braintree Laboratories, INC. | $14.77 | 2023 | Sutab |
| Boston Scientific Corporation | $14.57 | 2022 | |
| Bioventus LLC | $14.20 | 2019 | |
| Allergan, INC. | $11.49 | 2020 | |
| Heraeus Medical, LLC. | $11.17 | 2024 | |
| Janssen Pharmaceuticals, INC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Zehner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.